GHP September 2016

GHP September 2016

Welcome to the September edition of Global Health & Pharma, which features a whole host of news and exciting features, including the announcement of one of the first proton beam therapy cancer treatment centres to be built in England by February 2018.

In an extended feature, Farrer Park Hospital (FPH), Singapore’s newest private healthcare service provider, provides a fascinating insight into innovation in hospital administration and incorporating the latest technology to support better decision making for better patient outcomes and shorter hospital stays.

Remaining topical and up-to-date, Elisabethann Wright of Hogan Lovells examines some of the key issues facing the pharmaceutical industry and identifies the key areas which need to be addressed as the UK progresses towards Brexit.

Looking to the future, emerging markets are the next big opportunity after the US according to Frost & Sullivan. Increased life expectancy, a growing aged population cohort, and the higher incidence of chronic lifestyle-related diseases are encouraging the use generic pharmaceuticals as governments and healthcare service providers strive to contain costs.

Ramboll’s Neil Harvey reveals that in order to meet the needs of future healthcare buildings, those who design and engineer such facilities need to think in the long term. While forecasts tell us that over the next 50 years, the number of people over 60 years of age is expected to surpass those under the age of 14, we must consider our changing needs.

I hope that you enjoy reading this packed edition

.Jonathan Miles, Editor

Related posts